Anzeige
Mehr »
Mittwoch, 16.09.2026 - Börsentäglich über 12.000 News
Kommerzialisierung der "Super-Exosomen"
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
RB

WKN: A40MF2 | ISIN: US7574683014 | Ticker-Symbol: 2RH
NASDAQ
15.09.26 | 21:08
0,570 US-Dollar
-0,89 % -0,005
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
REDHILL BIOPHARMA LTD ADR Chart 1 Jahr
5-Tage-Chart
REDHILL BIOPHARMA LTD ADR 5-Tage-Chart

Aktuelle News zur REDHILL BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
31.08.RedHill Biopharma Divests Talicia Stake to Apotex Subsidiary for $18M12
31.08.RedHill Biopharma divests Talicia to Apotex for $18M upfront8
31.08.RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities560Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated...
► Artikel lesen
31.08.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer-
REDHILL BIOPHARMA Aktie jetzt für 0€ handeln
06.08.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer15
28.07.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer14
29.06.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer3
22.06.RedHill Biopharma closes $6 million private placement4
18.06.RedHill Biopharma raises $6M in private placement1
18.06.RedHill Biopharma announces up to $19.4M private placement4
18.06.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer1
09.06.RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation468The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most...
► Artikel lesen
08.06.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer4
03.06.RedHill Biopharma Ltd.: RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak755Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma...
► Artikel lesen
27.05.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer6
30.04.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer3
27.04.RedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights1.0602025 was a year of tenacity, strategic transactions and building traction for RedHill Talicia® business transformed: Formation of Talicia Holdings Inc. (THI) and...
► Artikel lesen
27.04.RedHill Biopharma Ltd. - 20-F, Annual and transition report of foreign private issuers-
22.04.RedHill Biopharma Ltd.: RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026518New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of...
► Artikel lesen
22.04.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer-
Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1